Table 1 Characteristics of patients diagnosed with a haematological malignancy: Haematological Malignancy Research Network (HMRN), 2004–2011
|  | Contacted N (%) | Consented to further contact N (%) | Questionnaire returned N (%) | Symptoms N (%) | Interval - Median Days (25–75 percentile – interquartile range) | |||
|---|---|---|---|---|---|---|---|---|
No | Yes | Total2 | Patient3 | Diagnostic4 | ||||
Total | 8858 (100) | 5038 (100) | 3329 (100) | 993(29.8) | 2336 (70.2) | 123 (55–277) | 17 (1–86.5) | 65 (26–155) |
Sex: | Â | Â | Â | Â | Â | Â | Â | Â |
Males | 4938 (55.7) | 2840 (56.4) | 1865 (56) | 617 (33.1) | 1248 (66.9) | 108 (52–252) | 16 (1–75) | 62 (24–152) |
Females | 3920 (44.3) | 2198 (43.6) | 1464 (44) | 376 (25.7) | 1088 (74.3) | 138 (62–315) | 26 (1–91) | 72 (29–158) |
Age at diagnosis (years): | Â | Â | Â | Â | Â | Â | Â | Â |
Median age (Range) | 69.2 (18.1-99.7) | 67.7 (18.1-96.8) | 67.4 (18.1-95.2) | 66.3 (18.1-95.2) | 69.9 (19.2-94.7) | - | - | - |
< 40 | 664 (7.5) | 330 (6.6) | 216 (6.5) | 25 (11.6) | 191 (88.4) | 120.5 (47–251) | 23.5 (1–92) | 55.5 (20–137) |
40-59 | 1821 (20.6) | 1138 (22.6) | 773 (23.2) | 178 (23.0) | 595 (77.0) | 124 (59–258) | 30 (1–85) | 64 (27–144) |
60-69 | 2087 (23.6) | 1362 (27) | 921 (27.7) | 295 (32.0) | 626 (68.0) | 119.5 (56–269) | 17 (1–91) | 67 (26–167) |
70-79 | 2701 (30.5) | 1506 (29.9) | 1018 (30.6) | 350 (34.4) | 668 (65.6) | 122 (57–311.5) | 16 (1–74) | 66 (27–142.5) |
80+ | 1585 (17.9) | 702 (13.9) | 401 (12) | 145 (36.2) | 256 (63.8) | 139 (48–354) | 16 (1–78) | 73 (28–189) |
Diagnostic group 1: | Â | Â | Â | Â | Â | Â | Â | Â |
Diffuse large B-cell lymphoma | 1342 (15.2) | 771 (15.3) | 503 (15.1) | 52 (10.3) | 451 (89.7) | 98 (53–192) | 9 (1–42) | 69 (37–134) |
Myeloma | 1263 (14.3) | 755 (15) | 493 (14.8) | 152 (30.8) | 341 (69.2) | 163 (84–306) | 31 (1–122) | 83 (34–167) |
Follicular lymphoma | 660 (7.5) | 413 (8.2) | 284 (8.5) | 51 (18.0) | 233 (82.0) | 112 (61–250) | 17 (1–76) | 65 (36–125.5) |
Myeloproliferative neoplasms | 1183 (13.4) | 674 (13.4) | 430 (12.9) | 205 (47.7) | 225 (52.3) | 215 (84–539) | 31 (1–168) | 77 (27–239) |
Marginal zone lymphoma | 616 (7) | 384 (7.6) | 247 (7.4) | 68 (27.5) | 179 (72.5) | 172 (77–385) | 30 (1–153) | 86.5 (27–193.5) |
Myelodysplastic syndromes | 720 (8.1) | 424 (8.4) | 267 (8) | 97 (36.3) | 170 (63.7) | 147 (55–393) | 16 (1–89) | 88 (24–249) |
Hodgkin lymphoma | 574 (6.5) | 292 (5.8) | 193 (5.8) | 26 (13.5) | 167 (86.5) | 158 (84–288) | 30 (2–77) | 87 (40–166) |
Chronic lymphocytic leukaemia | 650 (7.3) | 344 (6.8) | 265 (8) | 140 (52.8) | 125 (47.2) | 86 (38–238) | 22 (1–85) | 42 (12–88) |
Acute myeloid leukaemia | 538 (6.1) | 249 (4.9) | 161 (4.8) | 37 (23.0) | 124 (77.0) | 41 (17–85) | 13 (1–47) | 10 (5–32) |
Chronic myeloid leukaemia | 207 (2.3) | 143 (2.8) | 95 (2.9) | 28 (29.5) | 67 (70.5) | 96 (32–169) | 33.5 (4.5-127.5) | 9 (5–52) |
Mantle cell lymphoma | 159 (1.8) | 96 (1.9) | 65 (2) | 13 (20.0) | 52 (80.0) | 104 (58–258) | 21.5 (1–69.5) | 61 (29–144) |
Lymphoproliferative disorder NOS | 322 (3.6) | 153 (3) | 97 (2.9) | 53 (54.6) | 44 (45.4) | 324 (48–578) | 16 (1–30) | 185 (27–417) |
T-cell lymphoma | 148 (1.7) | 72 (1.4) | 52 (1.6) | 10 (19.2) | 42 (80.8) | 175 (70–306) | 18.5 (1–92) | 71 (39–167) |
Acute lymphoblastic leukaemia | 96 (1.1) | 50 (1) | 37 (1.1) | 8 (21.6) | 29 (78.4) | 32.5 (17–64) | 16 (2–26) | 12.5 (3–32) |
Myelofibrosis | 91 (1) | 54 (1.1) | 35 (1.1) | 12 (34.3) | 23 (65.7) | 314 (76–742) | 5 (1–66) | 93 (25–320) |
Myelodysplastic/Myeloproliferative neoplasms | 125 (1.4) | 66 (1.3) | 41 (1.2) | 18 (43.9) | 23 (56.1) | 421 (139–709) | 31 (16–308) | 128 (27–840) |
T-cell leukaemia | 62 (0.7) | 37 (0.7) | 32 (1) | 13 (40.6) | 19 (59.4) | 502 (75–761) | 30 (3–153) | 61 (37–367) |
Hairy cell leukaemia | 65 (0.7) | 43 (0.9) | 26 (0.8) | 10 (38.5) | 16 (61.5) | 88.5 (44–194) | 35 (1–138) | 16 (10–32) |
Burkitt lymphoma | 37 (0.4) | 18 (0.4) | 6 (0.2) | 0 (0.0) | 6 (100.0) | 67.5 (34–136) | 19 (4.5-30.5) | 36 (11–82.5) |